[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - The Lancet, 2021 - profiles.wustl.edu
Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - The Lancet, 2021 - scholars.aku.edu
Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group - Lancet, 2021 - openaccess.sgul.ac.uk
BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult
patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation …
patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group - Lancet, 2021 - qmro.qmul.ac.uk
BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult
patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation …
patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - The Lancet, 2021 - researchportal.ukhsa.gov.uk
Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - The Lancet, 2021 - ksascholar.dri.sa
Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group - 2021 - repository.cam.ac.uk
BACKGROUND: In this study, we aimed to evaluate the effects of tocilizumab in adult
patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation …
patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation …
[引用][C] Tocilizumab in patients admitted to hospital with COVID‐19 (RECOVERY): preliminary results of a randomised, controlled, open‐label, platform trial
RECOVERY Collaborative Group - medRxiv - cir.nii.ac.jp
Tocilizumab in patients admitted to hospital with COVID‐19 (RECOVERY): preliminary results
of a randomised, controlled, open‐label, platform trial | CiNii Research CiNii 国立情報学研究所 …
of a randomised, controlled, open‐label, platform trial | CiNii Research CiNii 国立情報学研究所 …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - The Lancet, 2021 - providence.elsevierpure.com
Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …